Jung YC, Han S, Hua L, et al. Kazinol-E is a specific inhibitor of ERK that suppresses the enrichment of a breast cancer stem-like cell population. Biochem Biophys Res Commun 2016; 470(2): 294-9.
Zuo ZQ, Chen KG, Yu XY, et al. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials 2016; 82: 48-59.
Hong IS, Jang GB, Lee HY, Nam JS. Targeting cancer stem cells by using the nanoparticles. Int J Nanomedicine 2015; 10: 251-60.
Toledo-Guzmán ME, Bigoni-Ordóñez GD, Hernández MI, Ortiz-Sánchez E. Cancer stem cell impact on clinical oncology. World J Stem Cells 2018; 10(12): 183-95.
Smita Bonde SN. Advances in liposomal drug delivery system: Fascinating types and potential applications. Int J Appl Pharm 2017; 9(3): 1-7.
Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther 2019; 34(1): 1-8.
Gener P, Rafael DF, Fernández Y, et al. SSJ. Cancer stem cells and personalized cancer nanomedicine. Nanomedicine 2016; 11(3): 307-20.
Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 2014; 453(1): 112-6.
Li SY, Sun R, Wang HX, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release 2015; 205: 7-14.
Krishnamurthy S, Ke X, Yang YY. Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells. Nanomedicine 2015; 10(1): 143-60.
Minko T, Dharap SS, Pakunlu RIWY. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004; 5(4): 389-406.
Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
Suri SS, Fenniri HSB, Ravichandran R. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007; 5(1-4): 17-33.
Anitha P, Bhargavi J, Sravani G, Aruna B, Ramkanth S. Recent progress of dendrimers in drug delivery for cancer therapy. Int J Appl Pharm 2018; 10(5): 34-42.
Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol 2014; 5: 1-22.
Minko T, Pakunlu RI, Wang Y, Khandare JJSM. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 2006; 6(6): 537-52.
Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. Breast Cancer Basic Clin Res 2015; 9: 17-34.
Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008; 129(1): 18-25.
Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin
plus tamoxifen on the breast cancer and cancer stem cells. 2010; 13(2): 136-51.
Liao D, Liu Z, Wrasidlo W, et al. Synthetic enzyme inhibitor: A novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed Nanotechnol Biol Med 2011; 7(6): 665-73.
Liao D, Liu Z, Wrasidlo WJ, et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res 2011; 71(17): 5688-96.
Zhang L, Yao HJ, Yu Y, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012; 33(2): 565-82.
Sun Y, Kim HS, Saw PE, Jon S, Moon WK. Targeted therapy for breast cancer stem cells by liposomal delivery of siRNA against Fibronectin EDB. Adv Healthc Mater 2015; 4(11): 1675-80.
Ahmad A, Mondal SK, Mukhopadhyay D, Banerjee R, Alkharfy KM. Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol Pharm 2016; 13(3): 1081-8.